Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Shareholder Meeting (November 2010)
17 slides from Genetic Technologies's shareholder meeting presentation, Nov 26, 2010
Slide 1: Annual General Meeting
Annual General Meeting Dr Paul MacLeman, CEO TreeTops, Melbourne Museum, November 24, 2010 Building a global diagnostic products business
Slide 2: Forward looking statements
Forward looking statements This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business achievements/performance
Slide 3: Your Company
Your Company Back to basics approach to growing our business More products in more territories Reduced costs Strategy for meaningful growth and profitability Focused on a few measurable, deliverable milestones 3
Slide 4: Today's Presentation
Today’s Presentation Review of last year’s objectives Progress towards these objectives Goals for this year 4
Slide 5: 2010 Goals and Outcomes
2010 Goals and Outcomes Medical Animal Profiling Leading provider of cancer management tools, Asia Pacific Global relationships or M&A accessing leading products Leading provider of breeding health management Expand into household, veterinary and pedigree channels Leading private provider in the reg
Slide 6: Licensing Program: Resources for Growth
Licensing Program: Resources for Growth World class in- house licensing team Parties joined suit #1: settled Beckman Coulter Partnership with Sheridan Ross PC, a full service Orchid Cellmark intellectual property law firm based in Colorado Gen- Probe Interleukin Genetics assertion candidates joined
Slide 7: Australian Operations
Australian Operations Sales increases, examples Royal Women's Hospital Royal North Shore Hospital Chinese Kennel Union Service, price and competency Cost containment Head count 85 to 58 last 12mm Divestment non-productive assets Canine re-structuring More focus on what we are good at $1MM recurrent
Slide 8: Medical Strategy Delivers Early Results
Medical Strategy Delivers Early Results Planned Q1 2011 launch 8
Slide 9: Compelling Market Opportunity
Compelling Market Opportunity The US market for existing breast cancer molecular diagnostics is approximately $690MM* Referenced by: BRACAnalysis (Myriad) sales ~$320MM in 7 years OncotypeDx (Genomics Health) ~$200MM in 5 years Other players (Genzyme, Clarient, etc.) make up the balance BREVAGen™ ta
Slide 10: BREVAGen Nearing US Launch
BREVAGen™ Nearing - US Launch Marketing via subsidiary Phenogen Sciences Inc. (USA), GTG RoW Large global opportunity Preparing for staged US launch Q1 2011 Unique, patented product Peer reviewed validation study Oct10 Journal of National Cancer Institutes CLIA registration in train: Australia’s fir
Slide 11: BREVAGen Opportunity
BREVAGen ™ Opportunity Short Term ADH/ALH/LCIS (400k) Intermediate Biopsy (1M*) All Biopsy Patients (1.6M) All Mammogram Targets** (60.3M) Longer Term *Estimate from PhenoGen Sciences **49.5M Caucasian women, 7.9M African American women, 2.9M Asian American women ages 40-80
Slide 12: BREVAGen – World's First Validated Non-Familial Breast Cancer Test
BREVAGen™ – World’s First Validated Non-Familial Breast Cancer Test (85% of cases) Gail Score Mammogram 1.6 million breast biopsies per year (USA) 1 million patients indeterminate management based upon histopathology BREVAGen re-classifies ~25% of these and thus enables preventive SERM therapy SERMs
Slide 13: Financials
Financials Improvements in both product Cost reductions and rising and more strongly, in licensing revenues have produced a revenues strong trend towards positive cash flows and profitability 13
Slide 14: 2011 Goals
2011 Goals Global business Successful launch of BREVAGen™ in US (& EU) Partner with pharmaceutical companies for development of companion diagnostics Australian operations Move towards critical mass for Australian sales & operations Business development and M&A Seek out other late stage product oppo
Slide 15: Summary
Summary Genetic Technologies is becoming a leading global provider of cancer management tools BREVAGen™ the 1st in global portfolio New products, customers and revenues delivered to plan Revenue up, costs down, moving closer to profitability & meeting milestones Experienced management achieving goal
Slide 16: Taking Our Products to the World
Genetic Technologies Ltd Taking Our Products to the World Phenogen Sciences Inc 16
Slide 17: Thank You
Thank You Dr Paul D R MacLeman CEO Genetic Technologies Ltd Phone +61 3 8412 7000 Cell +61 419 401 445 Email paul.macleman@gtglabs.com 17
Genetic Technologies — Shareholder Meeting (November 2010) on 6ix